The growing burden of blood cancers and continuous advancements in targeted therapies have significantly increased demand within the lenalidomide drug market. As the multiple myeloma treatment market expands and the hematologic cancer therapeutics market evolves with more personalized treatment approaches, lenalidomide remains one of the most widely prescribed...